<DOC>
	<DOC>NCT00368706</DOC>
	<brief_summary>To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid</brief_summary>
	<brief_title>A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Patients willing and able to complete the micturition diary correctly Patients experiencing frequency of micturition as verified in the diary Patients experiencing significant post void residual volume OAB symptoms including urinary frequency, urgency or urge incontinence for 3 months or more. Significant post void residual volume Patients with indwelling catheters or practicing intermittent self catheterization Known or suspected hypersensitivity to solifenacin succinate or other anticholinergics or lactose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>solifenacin</keyword>
	<keyword>Overactive bladder</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Treatment outcomes</keyword>
	<keyword>VESIcare</keyword>
</DOC>